← Back to all signals
RESEARCH PAPER ANALYSIS

Functional changes in spinal circuitry in essential tremor revealed with analysis of intramuscle synergies.

This study finds that intramuscle synergies—patterns of motor unit recruitment at the spinal level—are selectively disrupted in essential tremor (reduced flexibility of motor unit recruitment) but are not altered in Parkinson's disease compared with controls.

PMID41914892
JournalJournal of neurophysiology
Publication Date2026-05-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This study finds that intramuscle synergies—patterns of motor unit recruitment at the spinal level—are selectively disrupted in essential tremor (reduced flexibility of motor unit recruitment) but are not altered in Parkinson's disease compared with controls.

WHY IT MATTERS

Research significance

The work identifies a potential spinal-level biomarker and mechanistic target for essential tremor interventions, but it offers limited direct actionable insight for Parkinson's therapeutic discovery.

ABSTRACT

Source abstract

Essential tremor (ET) is one of the most common movement disorders and is marked by centrally generated oscillations that interfere with stable hand function. The contribution of spinal circuitry to impaired movement stability remains largely unexplored. In this study, we assessed intramuscle synergies as a potential biomarker of spinal deficits during accurate cyclic force production in individuals with ET and compared them with those in patients with Parkinson's disease (PD), age-matched controls (AMC), and young adult controls. Motor unit activity was extracted through surface EMG decomposition of flexor digitorum superficialis, and force-stabilizing synergies were quantified using the uncontrolled manifold framework. Across groups, multifinger synergies stabilizing total force were similar, with ET participants not different from AMC and PD. In contrast, intramuscle synergies were selectively disrupted in ET. The reduction of the synergy index in ET compared with all other groups was driven primarily by markedly lower variance that did not affect force magnitude, while variance affecting force output was comparable across groups. We conclude that ET shows reduced flexibility in motor unit recruitment and firing. These findings identify a previously unrecognized alteration at the level of spinal circuitry in ET during voluntary force control. Such impaired organization of motor units may contribute directly to difficulties maintaining stable hand action in daily tasks. Intramuscle synergy metrics thus represent a promising biomarker of spinal-level dysfunction in ET and a potential mechanistic target for future therapeutic interventions.NEW & NOTEWORTHY This is the first study exploring the recently described phenomenon of intramuscle synergies in neurological patients. Patients with essential tremor showed reduced indices of such synergies during cyclical finger force production compared with patients with Parkinson's disease and two groups of controls. This reduction reflected the reduced flexibility in the recruitment of motor unit groups. Studies of intramuscle synergies are promising to provide a sensitive biomarker of spinal circuitry.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic